Review article: Coeliac disease, new approaches to therapy

Alimentary Pharmacology and Therapeutics

Volumn 35, Issue 7, 2012, Pages 768-781

  Rashtak, S ^a   Murray, J A ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA4BETA7 INTEGRIN; BUDESONIDE; CHEMOKINE; CHEMOKINE CCL25; CHEMOKINE RECEPTOR CCR9; CHEMOKINE RECEPTOR CXCR3; CORTICOSTEROID; GAMMA INTERFERON ANTIBODY; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GASTROINTESTINAL AGENT; HLA ANTIGEN; HLA DQ2 ANTIGEN; IMIDAZOLE DERIVATIVE; INFLIXIMAB; INTEGRIN; INTERLEUKIN 10; INTERLEUKIN 15 ANTIBODY; KCC 009; L 682777; LARAZOTIDE; MUCOSAL ADDRESSIN CELL ADHESION MOLECULE 1; NATALIZUMAB; PLACEBO; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; R 283; UNCLASSIFIED DRUG; ZONULIN;

ABSENCE OF SIDE EFFECTS; ALTERNATIVE MEDICINE; ANTIGEN PRESENTATION; BINDING AFFINITY; CELIAC DISEASE; CLINICAL EFFECTIVENESS; CROHN DISEASE; CYTOKINE PRODUCTION; DETOXIFICATION; DIET RESTRICTION; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG TARGETING; ENTERITIS; ENZYME INHIBITION; GASTROINTESTINAL SYMPTOM; GLUTEN FREE DIET; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; INNATE IMMUNITY; LIGAND BINDING; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RECEPTOR BLOCKING; REVIEW; SAFETY; TREATMENT INDICATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VACCINATION; WHEAT;

CELIAC DISEASE; DIET, GLUTEN-FREE; DRUG DESIGN; GLUTENS; HUMANS; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TIME FACTORS; TRITICUM;

EID: 84858285419     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2012.05013.x     Document Type: Review

References (120)

1. Marsh MN,. Gluten, major histocompatibility complex, and the small intestine. A molecular and immunobiologic approach to the spectrum of gluten sensitivity ('celiac sprue'). Gastroenterology 1992; 102: 330-54.
2. Green PH, Cellier C,. Celiac disease. N Engl J Med 2007; 357: 1731-43.
3. American Gastroenterological Association medical position statement: Celiac Sprue. Gastroenterology 2001; 120: 1522-5.
4. Murray JA, Van Dyke C, Plevak MF, et al,. Trends in the identification and clinical features of celiac disease in a North American community, 1950-2001. Clin Gastroenterol Hepatol 2003; 1: 19-27. (Pubitemid 37254468)
5. Dube C, Rostom A, Sy R, et al,. The prevalence of celiac disease in average-risk and at-risk Western European populations: a systematic review. Gastroenterology 2005; 128: S57-67. (Pubitemid 40460823)
6. Catassi C, Ratsch IM, Fabiani E, et al,. Coeliac disease in the year 2000: exploring the iceberg. Lancet 1994; 343: 200-3.
7. Zone JJ,. Skin manifestations of celiac disease. Gastroenterology 2005; 128: S87-91. (Pubitemid 40460827)
8. Bushara KO,. Neurologic presentation of celiac disease. Gastroenterology 2005; 128: S92-7. (Pubitemid 40460828)
9. Green PH, Jabri B,. Coeliac disease. Lancet 2003; 362: 383-91. (Pubitemid 36945070)
10. Green PH,. The many faces of celiac disease: clinical presentation of celiac disease in the adult population. Gastroenterology 2005; 128: S74-8. (Pubitemid 40460825)
11. Abdulkarim AS, Murray JA,. Review article: the diagnosis of coeliac disease. Aliment Pharmacol Ther 2003; 17: 987-95. (Pubitemid 36560798)
12. Rashtak S, Murray JA,. Tailored testing for celiac disease. Ann Intern Med 2007; 147: 339-41. (Pubitemid 351664561)
13. van derWindt DA, Jellema P, Mulder CJ, et al,. Diagnostic testing for celiac disease among patients with abdominal symptoms: a systematic review. JAMA 2010; 303: 1738-46.
14. Hopper AD, Cross SS, Hurlstone DP, et al., Pre-endoscopy serological testine for coeliac disease: evaluation of a clinical decision tool. BMJ 2007; 334: 729.
15. Kurppa K, Collin P, Viljamaa M, et al,. Diagnosing mild enteropathy celiac disease: a randomized, controlled clinical study. Gastroenterology 2009; 136: 816-23.
16. See J, Murray JA,. Gluten-free diet: the medical and nutrition management of celiac disease. Nutr Clin Pract 2006; 21: 1-15. (Pubitemid 43190701)
17. Rubio-Tapia A, Murray JA,. Celiac disease. Curr Opin Gastroenterol 2010; 26: 116-22.
18. Sollid LM, Lundin KE,. Diagnosis and treatment of celiac disease. Mucosal Immunol 2009; 2: 3-7.
19. Di Sabatino A, Corazza GR,. Coeliac disease. Lancet 2009; 373: 1480-93.
20. Holmes GK, Prior P, Lane MR, et al,. Malignancy in coeliac disease-effect of a gluten free diet. Gut 1989; 30: 333-8. (Pubitemid 19091159)
21. Catassi C, Fabiani E, Iacono G, et al,. A prospective, double-blind, placebo-controlled trial to establish safe gluten threshold for patients with celiac disease. Am J Clin Nutri 2007; 85: 160-6. (Pubitemid 46067630)
22. Peraaho M, Kaukinen K, Paasikivi K, et al., Wheat-starch-based gluten-free products in the treatment of newly detected coeliac disease: prospective and randomized study. Aliment Pharmacol Ther 2003; 17: 587-94. (Pubitemid 36384818)
23. Lee A, Newman JM,. Celiac diet: its impact on quality of life. J Am Diet Assoc 2003; 103: 1533-5. (Pubitemid 39220505)
24. Hall NJ, Rubin G, Charnock A,. Systematic review: adherence to a gluten-free diet in adult patients with coeliac disease. Aliment Pharmacol Ther 2009; 30: 315-30.
25. Thompson T, Lee AR, Grace T,. Gluten contamination of grains, seeds, and flours in the United States: a pilot study. J Am Diet Assoc 2010; 110: 937-40.
26. Thompson T, Mendez E,. Commercial assays to assess gluten content of gluten-free foods: why they are not created equal. J Am Diet Assoc 2008; 108: 1682-7.
27. Bardella MT, Velio P, Cesana BM, et al,. Coeliac disease: a histological follow-up study. Histopathology 2007; 50: 465-71. (Pubitemid 46328182)
28. Rubio-Tapia A, Rahim MW, See JA, et al,. Mucosal recovery and mortality in adults with celiac disease after treatment with a gluten-free diet. Am J Gastroenterol 2010; 105: 1412-20.
29. Jabri B, Sollid LM,. Mechanisms of disease: immunopathogenesis of celiac disease. Nat Clin Pract Gastroenterol Hepatol 2006; 3: 516-25. (Pubitemid 44322763)
30. Sollid LM,. Coeliac disease: dissecting a complex inflammatory disorder. Nat Rev Immunol 2002; 2: 647-55. (Pubitemid 37328722)
31. Molberg O, McAdam SN, Korner R, et al,. Tissue transglutaminase selectively modifies gliadin peptides that are recognized by gut-derived T cells in celiac disease. Nat Med 1998; 4: 713-7. (Pubitemid 28274673)
32. Anderson RP, Degano P, Godkin AJ, Jewell DP, Hill AV,. In vivo antigen challenge in celiac disease identifies a single transglutaminase-modified peptide as the dominant A-gliadin T-cell epitope. Nat Med 2000; 6: 337-42. (Pubitemid 30148628)
33. Jabri B, Kasarda DD, Green PH,. Innate and adaptive immunity: the yin and yang of celiac disease. Immunol Rev 2005; 206: 219-31. (Pubitemid 41105173)
34. Akobeng AK, Thomas AG,. Systematic review: tolerable amount of gluten for people with coeliac disease. Aliment Pharmacol Ther 2008; 27: 1044-52. (Pubitemid 351614885)
35. Dicke WK,. Treatment of celiac disease. Ned Tijdschr Geneeskd 1951; 95: 124-30.
36. Lerner A,. New therapeutic strategies for celiac disease. Autoimmun Rev 2010; 9: 144-7.
37. Sollid LM, Khosla C,. Future therapeutic options for celiac disease. Nat Clin Pract Gastroenterol Hepatol 2005; 2: 140-7. (Pubitemid 40812513)
38. Rubio-Tapia A, Murray JA,. Classification and management of refractory coeliac disease. Gut 2010; 59: 547-57.
39. Lanzini A, Lanzarotto F, Villanacci V, et al,. Complete recovery of intestinal mucosa occurs very rarely in adult coeliac patients despite adherence to gluten-free diet. Aliment Pharmacol Ther 2009; 29: 1299-308.
40. Selby WS, Painter D, Collins A, et al,. Persistent mucosal abnormalities in coeliac disease are not related to the ingestion of trace amounts of gluten. Scand J Gastroenterol 1999; 34: 909-14. (Pubitemid 29470571)
41. Aziz I, Evans KE, Papageorgiou V, Sanders DS,. Are patients with coeliac disease seeking alternative therapies to a gluten-free diet? J Gastrointestin Liver Dis 2011; 20: 27-31.
42. Schuppan D, Junker Y, Barisani D,. Celiac disease: from pathogenesis to novel therapies. Gastroenterology 2009; 137: 1912-33.
43. Mezaize S, Chevallier S, Le Bail A, et al,. Optimization of gluten-free formulations for French-style breads. J Food Sci 2009; 74: E140-6.
44. Moroni AV, Dal Bello F, Arendt EK,. Sourdough in gluten-free bread-making: an ancient technology to solve a novel issue? Food Microbiol 2009; 26: 676-84.
45. Feldman M,. The origin of cultivated wheat-A History of Wheat Breeding. London: Lavoisier, 2001.
46. Molberg O, Uhlen AK, Jensen T, et al,. Mapping of gluten T-cell epitopes in the bread wheat ancestors: implications for celiac disease. Gastroenterology 2005; 128: 393-401. (Pubitemid 40431091)
47. Spaenij-Dekking L, Kooy-Winkelaar Y, van Veelen P, et al,. Natural variation in toxicity of wheat: potential for selection of nontoxic varieties for celiac disease patients. Gastroenterology 2005; 129: 797-806. (Pubitemid 41242672)
48. van den Broeck HC, van Herpen TW, Schuit C, et al,. Removing celiac disease-related gluten proteins from bread wheat while retaining technological properties: a study with Chinese Spring deletion lines. BMC Plant Biol 2009; 9: 41.
49. Tye-Din JA, Stewart JA, Dromey JA, et al., Comprehensive, quantitative mapping of T cell epitopes in gluten in celiac disease. Sci Transl Med 2010; 2: 41ra51.
50. Zandonadi RP, Botelho RB, Araujo WM,. Psyllium as a substitute for gluten in bread. J Am Diet Assoc 2009; 109: 1781-4.
51. Di Cagno R, De Angelis M, Auricchio S, et al,. Sourdough bread made from wheat and nontoxic flours and started with selected lactobacilli is tolerated in celiac sprue patients. Appl Environ Microbiol 2004; 70: 1088-96. (Pubitemid 38568235)
52. Cerf-Bensussan N, Matysiak-Budnik T, Cellier C, et al,. Oral proteases: a new approach to managing coeliac disease. Gut 2007; 56: 157-60.
53. Gass J, Bethune MT, Siegel M, et al,. Combination enzyme therapy for gastric digestion of dietary gluten in patients with celiac sprue. Gastroenterology 2007; 133: 472-80. (Pubitemid 47187353)
54. Stenman SM, Lindfors K, Venäläinen JI, et al,. Degradation of coeliac disease-inducing rye secalin by germinating cereal enzymes: diminishing toxic effects in intestinal epithelial cells. Clin Exp Immunol 2010; 161: 242-9.
55. Pinier M, Verdu EF, Nasser-Eddine M, et al,. Polymeric binders suppress gliadin-induced toxicity in the intestinal epithelium. Gastroenterology 2009; 136: 288-98.
56. Liang L, Pinier M, Leroux JC, et al,. Interaction of alpha-gliadin with polyanions: design considerations for sequestrants used in supportive treatment of celiac disease. Biopolymers 2010; 93: 418-28.
57. Schneeberger EE, Lynch RD,. The tight junction: a multifunctional complex. Am J Physiol Cell Physiol 2004; 286: C1213-28. (Pubitemid 38649971)
58. van Elburg RM, Uil JJ, Mulder CJ, et al,. Intestinal permeability in patients with coeliac disease and relatives of patients with coeliac disease. Gut 1993; 34: 354-7. (Pubitemid 23080261)
59. Monsuur AJ, de Bakker PI, Alizadeh BZ, et al,. Myosin IXB variant increases the risk of celiac disease and points toward a primary intestinal barrier defect. Nat Genet 2005; 37: 1341-4. (Pubitemid 41722189)
60. Fasano A, Not T, Wang W, et al,. Zonulin, a newly discovered modulator of intestinal permeability, and its expression in coeliac disease. Lancet 2000; 355: 1518-9. (Pubitemid 30237361)
61. Wang W, Uzzau S, Goldblum SE, et al,. Human zonulin, a potential modulator of intestinal tight junctions. J Cell Sci 2000; 113 (Pt 24): 4435-40. (Pubitemid 32117904)
62. Fasano A, Uzzau S,. Modulation of intestinal tight junctions by Zonula occludens toxin permits enteral administration of insulin and other macromolecules in an animal model. J Clin Invest 1997; 99: 1158-64. (Pubitemid 27142750)
63. Lammers KM, Lu R, Brownley J, et al,. Gliadin induces an increase in intestinal permeability and zonulin release by binding to the chemokine receptor CXCR3. Gastroenterology 2008; 135: 194-204.
64. Tripathi A, Lammers KM, Goldblum S, et al,. Identification of human zonulin, a physiological modulator of tight junctions, as prehaptoglobin-2. PNAS 2009; 106: 16799-804.
65. Paterson BM, Lammers KM, Arrieta MC, et al,. The safety, tolerance, pharmacokinetic and pharmacodynamic effects of single doses of AT-1001 in coeliac disease subjects: a proof of concept study. Aliment Pharmacol Ther 2007; 26: 757-66. (Pubitemid 47246202)
66. Klöck C, Jin X, Choi K, et al,. Acylideneoxoindoles: a new class of reversible inhibitors of human transglutaminase 2. Bioorg Med Chem Lett 2010; 21: 2692-6.
67. van de Wal Y, Kooy YM, van Veelen P, et al., Glutenin is involved in the gluten-driven mucosal T cell response. Eur J Immunol 1999; 10: 3133-9. (Pubitemid 29484203)
68. Molberg O, McAdam S, Lundin KE, et al,. T cells from celiac disease lesions recognize gliadin epitopes deamidated in situ by endogenous tissue transglutaminase. Eur J Immunol 2001; 31: 1317-23. (Pubitemid 32454680)
69. Freund KF, Doshi KP, Gaul SL, et al,. Transglutaminase inhibition by 2-[(2-oxopropyl)thio]imidazolium derivatives: mechanism of factor XIIIa inactivation. Biochemistry 1994; 33: 10109-19. (Pubitemid 24286091)
70. Maiuri L, Ciacci C, Ricciardelli I, et al,. Unexpected role of surface transglutaminase type II in celiac disease. Gastroenterology 2005; 129: 1400-13. (Pubitemid 41597382)
71. Szondy Z, Sarang Z, Molnar P, et al,. Transglutaminase 2-/- mice reveal a phagocytosis-associated crosstalk between macrophages and apoptotic cells. Proc Natl Acad Sci U S A 2003; 100: 7812-7. (Pubitemid 36760052)
72. Choi K, Siegel M, Piper JL, et al,. Chemistry and biology of dihydroisoxazole derivatives: selective inhibitors of human transglutaminase 2. Chem Biol 2005; 12: 469-75. (Pubitemid 40588922)
73. Watts RE, Siegel M, Khosla C,. Structure-activity relationship analysis of the selective inhibition of transglutaminase 2 by dihydroisoxazoles. J Med Chem 2006; 49: 7493-501. (Pubitemid 44913408)
74. Sollid LM, Thorsby E,. HLA susceptibility genes in celiac disease: genetic mapping and role in pathogenesis. Gastroenterology 1993; 105: 910-22. (Pubitemid 23249504)
75. Xia J, Bergseng E, Fleckenstein B, et al,. Cyclic and dimeric gluten peptide analogues inhibiting DQ2-mediated antigen presentation in celiac disease. Bioorg Med Chem 2007; 15: 6565-73. (Pubitemid 47302312)
76. Xia J, Siegel M, Bergseng E, et al,. Inhibition of HLA-DQ2-mediated antigen presentation by analogues of a high affinity 33-residue peptide from alpha2-gliadin. J Am Chem Soc 2006; 128: 1859-67. (Pubitemid 43277324)
77. Jüse U, van de Wal Y, Koning F, Sollid LM, Fleckenstein B,. Design of new high-affinity peptide ligands for human leukocyte antigen-DQ2 using a positional scanning peptide library. Hum Immunol 2010; 71: 475-81.
78. Rubio-Tapia A, Talley NJ, Gurudu SR, et al,. Gluten-free diet and steroid treatment are effective therapy for most patients with collagenous sprue. Clin Gastroenterol Hepatol 2010; 8: 344-9.
79. Ciacci C, Maiuri L, Russo I, et al,. Efficacy of budesonide therapy in the early phase of treatment of adult coeliac disease patients with malabsorption: an in vivo/in vitro pilot study. Clin Exp Pharmacol Physiol 2009; 36: 1170-6.
80. Jamma S, Leffler DA, Dennis M, et al,. Small intestinal release mesalamine for the treatment of refractory celiac disease type I. J Clin Gastroenterol 2011; 45: 30-3.
81. Przemioslo RT, Lundin KE, Sollid LM, et al,. Histological changes in small bowel mucosa induced by gliadin sensitive T lymphocytes can be blocked by anti-interferon gamma antibody. Gut 1995; 36: 874-9.
82. Bethune MT, Siegel M, Howles-Banerji S, et al,. Interferon-gamma released by gluten-stimulated celiac disease-specific intestinal T cells enhances the transepithelial flux of gluten peptides. J Pharmacol Exp Ther 2009; 329: 657-68.
83. Gillett HR, Arnott ID, McIntyre M, et al,. Successful infliximab treatment for steroid-refractory celiac disease: a case report. Gastroenterology 2002; 122: 800-5. (Pubitemid 34173833)
84. Costantino G, della Torre A, Lo Presti MA, et al,. Treatment of life-threatening type I refractory coeliac disease with long-term infliximab. Dig Liver Dis 2008; 40: 74-7. (Pubitemid 350246383)
85. Silano M, Vincentini O, De Vincenzi M,. Toxic, immunostimulatory and antagonist gluten peptides in celiac disease. Curr Med Chem 2009; 16: 1489-98.
86. Anderson RP, van Heel DA, Tye-Din JA, et al,. Antagonists and non-toxic variants of the dominant wheat gliadin T cell epitope in coeliac disease. Gut 2006; 55: 485-91.
87. Silano M, Leonardi F, Trecca A, Mancini E, Di Benedetto R, De Vincenzi M,. Prevention by a decapeptide from durum wheat of in vitro gliadin peptide-induced apoptosis in small-bowel mucosa from coeliac patients. Scand J Gastroenterol 2007; 42: 786-7. (Pubitemid 46763572)
88. Hue S, Mention JJ, Monteiro RC, et al,. A direct role for NKG2D/MICA interaction in villous atrophy during celiac disease. Immunity 2004; 21: 367-77. (Pubitemid 39208338)
89. Maiuri L, Ciacci C, Auricchio S, et al,. Interleukin 15 mediates epithelial changes in celiac disease. Gastroenterology 2000; 119: 996-1006.
90. Meresse B, Chen Z, Ciszewski C, et al,. Coordinated induction by IL15 of a TCR-independent NKG2D signaling pathway converts CTL into lymphokine-activated killer cells in celiac disease. Immunity 2004; 21: 357-66. (Pubitemid 39208337)
91. Di Sabatino A, Ciccocioppo R, Cupelli F, et al,. Epithelium derived interleukin 15 regulates intraepithelial lymphocyte Th1 cytokine production, cytotoxicity, and survival in coeliac disease. Gut 2006; 55: 469-77.
92. Mention JJ, Ben Ahmed M, Begue B, et al,. Interleukin 15: a key to disrupted intraepithelial lymphocyte homeostasis and lymphomagenesis in celiac disease. Gastroenterology 2003; 125: 730-45. (Pubitemid 37070691)
93. Yokoyama S, Watanabe N, Sato N, et al,. Antibody-mediated blockade of IL-15 reverses the autoimmune intestinal damage in transgenic mice that overexpress IL-15 in enterocytes. Proc Natl Acad Sci U S A 2009; 106: 15849-54.
94. Malamut G, El Machhour R, Montcuquet N, et al,. IL-15 triggers an antiapoptotic pathway in human intraepithelial lymphocytes that is a potential new target in celiac disease-associated inflammation and lymphomagenesis. J Clin Invest 2010; 120: 2131-43.
95. Braat H, Rottiers P, Hommes DW, et al,. A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease. Clin Gastroenterol Hepatol 2006; 4: 754-9. (Pubitemid 43841860)
96. Salvati VM, Mazzarella G, Gianfrani C, et al,. Recombinant human interleukin 10 suppresses gliadin dependent T cell activation in ex vivo cultured coeliac intestinal mucosa. Gut 2005; 54: 46-53. (Pubitemid 40007217)
97. Mulder CJ, Wahab PJ, Meijer JW, et al,. A pilot study of recombinant human interleukin-10 in adults with refractory coeliac disease. Eur J Gastroenterol Hepatol 2001; 13: 1183-8. (Pubitemid 33015884)
98. Berlin C, Berg EL, Briskin MJ, et al,. Alpha 4 beta 7 integrin mediates lymphocyte binding to the mucosal vascular addressin MAdCAM-1. Cell 1993; 74: 185-95. (Pubitemid 23219889)
99. Salmi M, Jalkanen S,. Molecules controlling lymphocyte migration to the gut. Gut 1999; 45: 148-53. (Pubitemid 29301861)
100. Di Sabatino A, Rovedatti L, Rosado MM, et al,. Increased expression of mucosal addressin cell adhesion molecule 1 in the duodenum of patients with active celiac disease is associated with depletion of integrin alpha4beta7-positive T cells in blood. Hum Pathol 2009; 40: 699-704.
101. Ghosh S, Goldin E, Gordon FH, et al,. Natalizumab for active Crohn's disease. N Engl J Med 2003; 348: 24-32. (Pubitemid 36026343)
102. Zabel BA, Agace WW, Campbell JJ, et al,. Human G protein-coupled receptor GPR-9-6/CC chemokine receptor 9 is selectively expressed on intestinal homing T lymphocytes, mucosal lymphocytes, and thymocytes and is required for thymus-expressed chemokine-mediated chemotaxis. J Exp Med 1999; 190: 1241-56.
103. Rivera-Nieves J, Ho J, Bamias G, et al,. Antibody blockade of CCL25/CCR9 ameliorates early but not late chronic murine ileitis. Gastroenterology 2006; 131: 1518-29. (Pubitemid 44708936)
104. Keshav S, Ungashe S, Zheng W, et al,. Ccx282-B, an orally active inhibitor of chemokine receptor Ccr9, shows anti-inflammatory & clinical activity in the treatment of Crohn's disease. Gastroenterology 2007; 132: A157 A157.
105. Booth V, Keizer DW, Kamphuis MB, et al,. The CXCR3 binding chemokine IP-10/CXCL10: structure and receptor interactions. Biochemistry 2002; 41: 10418-25.
106. Rashtak S, Marietta EV, Murray JA,. Gliadin stimulation of monocytes leads to increased expression of multiple T cell recruiting chemokines: a novel innate immune response. Clin Immunol 2010; 135 (Suppl. S): S47.
107. Hopman EG, von Blomberg ME, Batstra MR, et al,. Gluten tolerance in adult patients with celiac disease 20 years after diagnosis? Eur J Gastroenterol Hepatol 2008; 20: 423-9. (Pubitemid 351533879)
108. Bardella MT, Fredella C, Trovato C, et al,. Long-term remission in patients with dermatitis herpetiformis on a normal diet. Br J Dermatol 2003; 149: 968-71. (Pubitemid 37541980)
109. Vickery BP, Burks AW,. Immunotherapy in the treatment of food allergy: focus on oral tolerance. Curr Opin Allergy Clin Immunol 2009; 9: 364-70.
110. Maurano F, Siciliano RA, De Giulio B, et al,. Intranasal administration of one alpha gliadin can downregulate the immune response to whole gliadin in mice. Scand J Immunol 2001; 53: 290-5. (Pubitemid 32193696)
111. Senger S, Luongo D, Maurano F, et al,. Intranasal administration of a recombinant alpha-gliadin down-regulates the immune response to wheat gliadin in DQ8 transgenic mice. Immunol Lett 2003; 88: 127-34. (Pubitemid 36859976)
112. Huibregtse IL, Marietta EV, Rashtak S, et al,. Induction of antigen-specific tolerance by oral administration of Lactococcus lactis delivered immunodominant DQ8-restricted gliadin peptide in sensitized nonobese diabetic Abo Dq8 transgenic mice. J Immunol 2009; 183: 2390-6.
113. Croese J, O'Neil J, Masson J, et al,. A proof of concept study establishing Necator americanus in Crohn's patients and reservoir donors. Gut 2006; 55: 136-7. (Pubitemid 41820655)
114. Inoculating Celiac Disease Patients With the Human Hookworm Necator Americanus: Evaluating Immunity and Gluten-Sensitivity. Available at:; 2009.
115. Daveson AJ, Jones DM, Gaze S, et al,. Effect of hookworm infection on wheat challenge in celiac disease-a randomized double-blinded controlled trial. PLoS ONE 2011; 6: e17366.
116. Keech CL, Dromey J, Chen ZJ, et al,. Immune Tolerance Induced By Peptide Immunotherapy in An HLA Dq2-Dependent Mouse Model of Gluten Immunity. Gastroenterology 2009; 136: A57 -A57.
117. Collado MC, Donat E, Ribes-Koninckx C, et al,. Specific duodenal and faecal bacterial groups associated with paediatric coeliac disease. J Clin Pathol 2009; 62: 264-9.
118. Tursi A, Brandimarte G, Giorgetti G,. High prevalence of small intestinal bacterial overgrowth in celiac patients with persistence of gastrointestinal symptoms after gluten withdrawal. Am J Gastroenterol 2003; 98: 839-43. (Pubitemid 36576311)
119. Zhao J, de Vera J, Narushima S, et al,. R-spondin1, a novel intestinotrophic ameliorates experimental colitis in mice. Gastroentrology 2007; 132: 1331-43. (Pubitemid 46627581)
120. Rubio-Tapia A, Abdulkarim AS, Wiesner RH, et al,. Celiac disease autoantibodies in severe autoimmune liver disease and the effect of liver transplantation. Liver Int 2008; 28: 467-76. (Pubitemid 351411132)